Close Menu

NEW YORK – Bionano Genomics reported a 46 percent decrease in second quarter revenues after the close of the market on Thursday, attributable to customers shutting down labs in response to the COVID-19 pandemic.

For the quarter ended June 30, 2020, Bionano reported $1.2 million in revenues, down from $2.2 million for the year-ago period. Of those, $940,000 were product revenues and $242,000 were other revenues compared to $2 million in product revenues and $154,237 in other revenues in Q2 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.